Zim Laboratories Announces Q3 FY26 Results: Consolidated Profit at ₹439.76 Lakhs
Zim Laboratories reported its Q3 FY26 results. Consolidated revenue from operations was ₹10,865.93 lakhs and profit after tax was ₹439.76 lakhs for the quarter ended December 31, 2025. Standalone revenue from operations was ₹10,780.58 lakhs with profit after tax at ₹425.90 lakhs for the same period. The results were approved by the Board on February 11, 2026.
The announcement of quarterly financial results is a material event for investors and stakeholders, impacting investment decisions and stock valuation.
The company reported an increase in revenue and profit for the quarter compared to the previous year, indicating positive financial performance.
Zim Laboratories Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors, in their meeting held on February 11, 2026, approved these results. The company reported consolidated revenue from operations of ₹10,865.93 lakhs for the quarter, an increase from ₹9,633.03 lakhs in the same period last year. Consolidated profit after tax for the quarter stood at ₹439.76 lakhs, a rise from ₹400.08 lakhs in the corresponding quarter of the previous year. For the nine months ended December 31, 2025, consolidated revenue from operations was ₹26,912.67 lakhs, with a profit after tax of ₹209.81 lakhs. The standalone results also showed a similar trend, with revenue from operations at ₹10,780.58 lakhs and profit after tax at ₹425.90 lakhs for the quarter ended December 31, 2025. The limited review reports from Deloitte Haskins & Sells LLP, the statutory auditors, were enclosed with the results. The Board meeting commenced at 04:00 p.m. IST and concluded at 06:45 p.m. IST.
What to do with a filing like this
Zim Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zim Laboratories Limited. Read the original for the full detail.